Land: Israel
Språk: engelska
Källa: Ministry of Health
FENTANYL AS CITRATE
A.L. MEDI-MARKET LTD.
N01AH01
SOLUTION FOR INJECTION
FENTANYL AS CITRATE 0.05 MG / 1 ML
EPIDURAL, I.V
Required
HBM PHARMA S.R.O., SLOVAKIA
FENTANYL
For analgesic action of short duration during anesthtic periods (premedication induction and maintenance) and in the immediate postoperative period as need arises. As a narcotic analgesic supplement in general or regional anesthesia. For administration with neuroleptics (such as droperidol) as an anesthetic premedication for the induction of anesthesia and as an adjunct in the maintenance of general or regional anesthesia. For use as an anesthetic agent with oxygen in selected high-risk patients (open heart surgery or certain neurological or orthopedic procedures). By the epidural route for the postoperative management of pain following general surgical procedures and cesarean sections and as adjunct to general anesthesia.
2020-11-22
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fentanyl-Kalceks 0.05 mg/ml 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 0.05 mg (50 mcg) of fentanyl (as fentanyl citrate). Each ampoule of 2 ml contains 0.1 mg (100 mcg) of fentanyl (as fentanyl citrate). Each ampoule of 10 ml contains 0.5 mg (500 mcg) of fentanyl (as fentanyl citrate). Excipient with known effect Each ampoule of 2 ml contains 7.08 mg (0.31 mmol) sodium. Each ampoule of 10 ml contains 35.41 mg (1.54 mmol) sodium. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution for injection, free from visible particles. The pH of the solution is 4.0 to 7.5. Osmolality is approximately 285 mOsmol/kg. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Fentanyl-Kalceks 0.05 mg/ml is indicated: - For analgesic action of short duration during anesthetic periods (premedication, induction and maintenance) and in the immediate postoperative period, as need arises. - As a narcotic analgesic supplement in general or regional anesthesia. - For administration with a neuroleptic _[such as droperidol] _ as an anesthetic premedication, for the induction of anesthesia, and as an adjunct in the maintenance of general and regional anesthesia. - For use as an anaesthetic agent with oxygen in selected, high-risk patients (open heart surgery or certain neurological or orthopedic procedures). - By the epidural route for the postoperative management of pains following general surgical WARNING: RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINS OR OTHER CNS DEPRESSANTS • Concomitant use of opioids with benzodiazepins or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death (see section 4.5., Interaction with other medicinal products and other forms of interaction). • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Läs hela dokumentet